{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T10:38:47Z","timestamp":1786617527363,"version":"build-2736575974"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:00:00Z","timestamp":1786579200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:00:00Z","timestamp":1786579200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100008678","name":"Universit\u00e4t Leipzig","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100008678","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastrointest Canc"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Transarterial radioembolization (TARE) is an established locoregional therapy for advanced hepatocellular carcinoma (HCC). Prognosis depends on both tumor progression and hepatic function. Despite multiple scoring systems, predicting therapeutic benefit remains challenging.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods<\/jats:title>\n                    <jats:p>This study evaluated the prognostic performance of established scores (BCLC, HAP, CLIP, OKUDA, ALBI, MELD, and Child-Pugh) for survival after TARE in 86 patients with HCC and liver cirrhosis. Predictive accuracy for 3-, 6-, and 12-month survival was assessed using ROC curve analyses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The median age was 67 years, and the predominant etiologies were alcohol-related and metabolic dysfunction\u2013associated steatotic liver disease. Only ALBI and OKUDA were significantly associated with overall survival (HR 3.10;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001 and HR 5.02;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.018, respectively). ALBI and CLIP showed the highest predictive accuracy for 3-, 6-, and 12-month survival. In multivariablee analysis, ALBI and OKUDA remained independent predictors of 12-month survival (HR 3.70;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.001 and HR 5.01;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.025, respectively). The ALBI score worsened significantly within 12 weeks after TARE (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The ALBI score was the strongest predictor of survival following TARE. In contrast, tumor burden showed limited prognostic relevance, underscoring hepatic functional reserve as a key determinant of outcomes after locoregional liver cancer therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s12029-026-01572-1","type":"journal-article","created":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T10:21:06Z","timestamp":1786616466000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prognostic Value of Liver Function and Tumor Burden Scores in Patients with HCC After Transarterial Radioembolization \u2013 Retrospective Single Center Analysis"],"prefix":"10.1007","volume":"57","author":[{"given":"Aaron","family":"Schindler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Beeskow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janett","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Ebel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timm","family":"Denecke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Seehofer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Lincke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osama","family":"Sabri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Berg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"van B\u00f6mmel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,13]]},"reference":[{"issue":"10127","key":"1572_CR1","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/S0140-6736(18)30010-2","volume":"391","author":"A Forner","year":"2018","unstructured":"Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet. 2018;391(10127):1301\u201314. https:\/\/doi.org\/10.1016\/S0140-6736(18)30010-2.","journal-title":"Lancet"},{"key":"1572_CR2","unstructured":"World Health Organization. Global Cancer Observatory (GCO). Cancer Today 2020. http:\/\/gco.iarc.fr\/today\/home. Accessed 31 Jan 2026."},{"issue":"1","key":"1572_CR3","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","volume":"69","author":"European Association for the Study of the Liver","year":"2018","unstructured":"European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182\u2013236.","journal-title":"J Hepatol"},{"issue":"6","key":"1572_CR4","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/j.annonc.2021.02.014","volume":"32","author":"A Vogel","year":"2023","unstructured":"Vogel A, Martinelli E, ESMO Guidelines Committee. Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO Clinical Practice Guidelines. Ann Oncol. 2023;32(6):801\u20135.","journal-title":"Ann Oncol"},{"key":"1572_CR5","unstructured":"German S. 3-Leitlinie Diagnostik und Therapie des Hepatozellul\u00e4ren Karzinoms und bili\u00e4rer Karzinome, Version 5.2, June 2025."},{"key":"1572_CR6","doi-asserted-by":"publisher","first-page":"e4631","DOI":"10.1016\/j.medcli.2020.09.022","volume":"156","author":"M Reig","year":"2021","unstructured":"Reig M, Forner A, \u00c1vila MA, et al. Diagnosis and treatment of hepatocellular carcinoma. Update of the consensus document of the AEEH, AEC, SEOM, SERAM, SERVEI, and SETH. Med Clin (Barc). 2021;156:e4631\u201346330.","journal-title":"Med Clin (Barc)"},{"issue":"2","key":"1572_CR7","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1007\/s00270-014-1012-0","volume":"38","author":"MB Pitton","year":"2015","unstructured":"Pitton MB, Kloeckner R, Ruckes C, et al. Randomized comparison of selective internal radiotherapy (SIRT) versus drug-eluting bead transarterial chemoembolization (DEB-TACE) for the treatment of hepatocellular carcinoma. Cardiovasc Intervent Radiol. 2015;38(2):352\u201360.","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"11","key":"1572_CR8","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1007\/s00270-016-1426-y","volume":"39","author":"L Lobo","year":"2016","unstructured":"Lobo L, Yakoub D, Picado O, et al. Unresectable Hepatocellular Carcinoma: Radioembolization Versus Chemoembolization: A Systematic Review and Meta-analysis. Cardiovasc Intervent Radiol. 2016;39(11):1580\u20138.","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"19","key":"1572_CR9","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1200\/JCO.2017.76.0892","volume":"36","author":"PKH Chow","year":"2018","unstructured":"Chow PKH, Gandhi M, Tan S-B, et al. SIRveNIB: selective internal radiation therapy versus sorafenib in AsiaPacific patients with hepatocellular carcinoma. J Clin Oncol. 2018;36(19):1913\u201321.","journal-title":"J Clin Oncol"},{"key":"1572_CR10","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1016\/S1470-2045(17)30683-6","volume":"18","author":"V Vilgrain","year":"2017","unstructured":"Vilgrain V, Pereira H, Assenat E, et al. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial. Lancet Oncol. 2017;18:1624\u2013163.","journal-title":"Lancet Oncol"},{"key":"1572_CR11","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1016\/j.jhep.2019.08.006","volume":"71","author":"J Ricke","year":"2019","unstructured":"Ricke J, Kl\u00fcmpen HJ, Amthauer H, et al. Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma. J Hepatol. 2019;71:1164\u201374.","journal-title":"J Hepatol"},{"key":"1572_CR12","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.2967\/jnumed.120.242933","volume":"61","author":"M Venerito","year":"2020","unstructured":"Venerito M, Pech M, Canbay A, et al. NEMESIS: non-inferiority, individual patient meta-analysis of selective internal radiation therapy with yttrium-90 resin microspheres versus Sorafenib in advanced hepatocellular carcinoma. J Nucl Med. 2020;61:1736\u201342.","journal-title":"J Nucl Med"},{"key":"1572_CR13","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.jhep.2024.08.028","volume":"82","author":"EASL Clinical Practice","year":"2025","unstructured":"EASL Clinical Practice. Guidelines on the management of hepatocellular carcinoma. J Hepatol. 2025;82:315\u201374.","journal-title":"J Hepatol"},{"issue":"4","key":"1572_CR14","doi-asserted-by":"publisher","first-page":"877","DOI":"10.3390\/biomedicines14040877","volume":"14","author":"EL Fite","year":"2026","unstructured":"Fite EL, Sekar N, Venancius JS, et al. Bridging and Downstaging: Advances in Locoregional Therapy. Biomedicines. 2026;14(4):877. https:\/\/doi.org\/10.3390\/biomedicines14040877.","journal-title":"Biomedicines"},{"issue":"3","key":"1572_CR15","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.livres.2024.09.002","volume":"8","author":"W Abdelhamed","year":"2024","unstructured":"Abdelhamed W, Shousha H, El-Kassas M, et al. Portal vein tumor thrombosis in hepatocellular carcinoma patients: Is it the end? Liver Res. 2024;8(3):141\u201351. https:\/\/doi.org\/10.1016\/j.livres.2024.09.002.","journal-title":"Liver Res"},{"key":"1572_CR16","first-page":"1","volume":"1","author":"CG Child","year":"1964","unstructured":"Child CG, Turcotte JG. Surgery and portal hypertension. Major Probl Clin Surg. 1964;1:1\u201385.","journal-title":"Major Probl Clin Surg"},{"issue":"4","key":"1572_CR17","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1053\/he.2000.5852","volume":"31","author":"M Malinchoc","year":"2000","unstructured":"Malinchoc M, Kamath PS, Gordon FD, et al. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology. 2000;31(4):864\u201371.","journal-title":"Hepatology"},{"issue":"5","key":"1572_CR18","doi-asserted-by":"publisher","first-page":"100347","DOI":"10.1016\/j.jhepr.2021.100347","volume":"3","author":"CO Demirtas","year":"2021","unstructured":"Demirtas CO, D\u2019Alessio A, Rimassa L, et al. ALBI grade: Evidence for an improved model for liver functional estimation in patients with hepatocellular carcinoma. JHEP Rep. 2021;3(5):100347.","journal-title":"JHEP Rep"},{"issue":"6","key":"1572_CR19","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1200\/JCO.2014.57.9151","volume":"33","author":"PJ Johnson","year":"2015","unstructured":"Johnson PJ, Berhane S, Kagebayashi C, et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J Clin Oncol. 2015;33(6):550\u20138.","journal-title":"J Clin Oncol"},{"issue":"5","key":"1572_CR20","doi-asserted-by":"publisher","first-page":"840","DOI":"10.21037\/jgo.2018.05.14","volume":"9","author":"H Mohammadi","year":"2018","unstructured":"Mohammadi H, Abuodeh Y, Jin W, et al. Using the Albumin-Bilirubin (ALBI) grade as a prognostic marker for radioembolization of hepatocellular carcinoma. J Gastrointest Oncol. 2018;9(5):840\u20136.","journal-title":"J Gastrointest Oncol"},{"key":"1572_CR21","doi-asserted-by":"crossref","unstructured":"Antkowiak M, Gabr A, Das A et al. Prognostic role of albumin, bilirubin, and ALBI scores: analysis of 1000 patients with hepatocellular carcinoma undergoing radioembolization. Cancers (Basel). 2019;11(6).","DOI":"10.3390\/cancers11060879"},{"key":"1572_CR22","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s13550-021-00791-w","volume":"11","author":"O \u00d6cal","year":"2021","unstructured":"\u00d6cal O, Kupcinskas J, Morkunas E, et al. Prognostic value of baseline interleukin 6 levels in liver decompensation and survival in HCC patients undergoing radioembolization. EJNMMI Res. 2021;11:51.","journal-title":"EJNMMI Res"},{"key":"1572_CR23","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1002\/hep.510280322","volume":"28","author":"The Cancer of Liver Italian Program (CLIP)","year":"1998","unstructured":"The Cancer of Liver Italian Program (CLIP). Investigators. A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients. Hepatology. 1998;28:751\u20135.","journal-title":"Hepatology"},{"issue":"10","key":"1572_CR24","doi-asserted-by":"publisher","first-page":"2565","DOI":"10.1093\/annonc\/mdt247","volume":"24","author":"L Kadalayil","year":"2013","unstructured":"Kadalayil L, et al. A simple prognostic scoring system for patients receiving transarterial embolisation for hepatocellular cancer. Ann Oncol. 2013;24(10):2565\u201370. https:\/\/doi.org\/10.1093\/annonc\/mdt247.","journal-title":"Ann Oncol"},{"key":"1572_CR25","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1002\/1097-0142(19850815)56:4<918::AID-CNCR2820560437>3.0.CO;2-E","volume":"56","author":"K Okuda","year":"1985","unstructured":"Okuda K, Ohtsuki T, Obata H, et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer. 1985;56:918\u201328.","journal-title":"Cancer"},{"issue":"5","key":"1572_CR26","doi-asserted-by":"publisher","first-page":"623","DOI":"10.21873\/cdp.10373","volume":"4","author":"MP Ballester","year":"2024","unstructured":"Ballester MP, et al. Atezolizumab Plus Bevacizumab Treatment for Unresectable Hepatocellular Carcinoma: Real-life Experience from a Single Tertiary Centre in Spain and ALBI Score as a Survival Prognostic Factor. Cancer Diagn Progn. 2024;4(5):623\u201330. https:\/\/doi.org\/10.21873\/cdp.10373.","journal-title":"Cancer Diagn Progn"},{"issue":"24","key":"1572_CR27","doi-asserted-by":"publisher","first-page":"6089","DOI":"10.3390\/cancers14246089","volume":"14","author":"S Unome","year":"2022","unstructured":"Unome S, et al. Changes in ALBI Score and PIVKA-II within Three Months after Commencing Atezolizumab Plus Bevacizumab Treatment Affect Overall Survival in Patients with Unresectable Hepatocellular Carcinoma. Cancers (Basel). 2022;14(24):6089. 0.3390\/cancers14246089.","journal-title":"Cancers (Basel)"},{"issue":"9","key":"1572_CR28","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1097\/COC.0000000000000384","volume":"41","author":"B Gui","year":"2018","unstructured":"Gui B, Weiner AA, Nosher J, et al. Assessment of the albumin-bilirubin (ALBI) grade as a prognostic indicator for hepatocellular carcinoma patients treated with radioembolization. Am J Clin Oncol. 2018;41(9):861\u20136. https:\/\/doi.org\/10.1097\/COC.0000000000000384.","journal-title":"Am J Clin Oncol"},{"key":"1572_CR29","doi-asserted-by":"publisher","first-page":"934446","DOI":"10.3389\/fnume.2022.934446","volume":"2","author":"F Gelardi","year":"2022","unstructured":"Gelardi F, Rodari M, Pini C, et al. Front Nucl Med. 2022;2:934446. https:\/\/doi.org\/10.3389\/fnume.2022.934446 . eCollection 2022PMID: 39354974.","journal-title":"Front Nucl Med"},{"key":"1572_CR30","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1158\/1078-0432.CCR-24-2582","volume":"31","author":"G Cabibbo","year":"2025","unstructured":"Cabibbo G, Celsa C. Battaglia Set al. Early Hepatic Decompensation Identifies Patients with Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab or Sorafenib at Highest Risk of Death. Clin Cancer Res. 2025;31:543\u201350.","journal-title":"Clin Cancer Res"},{"key":"1572_CR31","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1159\/000529173","volume":"12","author":"A Vogel","year":"2023","unstructured":"Vogel A, Kelley RK, Johnson P, et al. Predictive and Prognostic Potential of Liver Function Assessment in Patients with Advanced Hepatocellular Carcinoma: A Systematic Literature Review. Liver Cancer. 2023;12:372\u201391.","journal-title":"Liver Cancer"},{"key":"1572_CR32","first-page":"610","volume":"13","author":"K Kyo-Pyo","year":"2024","unstructured":"Kyo-Pyo K, et al. Prognostic Efficacy of the Albumin-Bilirubin Score and Treatment Outcomes in Hepatocellular Outcomes: A Large-Scale Multi-Center Real-World Database study. Liver Cancer. 2024;13:610\u201328.","journal-title":"Liver Cancer"}],"container-title":["Journal of Gastrointestinal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-026-01572-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12029-026-01572-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-026-01572-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T10:21:10Z","timestamp":1786616470000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12029-026-01572-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,13]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1572"],"URL":"https:\/\/doi.org\/10.1007\/s12029-026-01572-1","relation":{},"ISSN":["1941-6636"],"issn-type":[{"value":"1941-6636","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,13]]},"assertion":[{"value":"26 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was conducted according to the guidelines of the Declaration of Helsinki and was approved by the Ethics Committee of Medical Research of the University of Leipzig (protocol code 132\/23-ek, 09.05.2023) for studies involving humans.","order":1,"name":"Ethics","label":"Approval of the research","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent was obtained from all subjects involved in the study.","order":2,"name":"Ethics","label":"Informed Consent","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Aaron Schindler has nothing to disclose. Janett Fischer has nothing to disclose. Anne-Bettina Beeskow has nothing to disclose. Sebastian Ebel has nothing to disclose. Timm Denecke has nothing to disclose. Thomas Lincke has nothing to disclose. Osama Sabri has nothing to disclose. Daniel Seehofer declares honoraria for lectures and\/or as an advisor from Chiesi, Olympus, Astellas, Novartis, SIRTEX, BTG, Johnson & Johnson. Florian van B\u00f6mmel declares honoraria from honoraria for lectures and\/or as an advisor from ADVANZ Pharma, Astra Zeneca, Bayer, BMS, Falk Foundation, Gilead Sciences, MSD, Novartis, Roche and StreamedUp!. Thomas Berg receipt of grants\/research supports from Abbvie, BMS, Gilead, MSD\/Merck, Humedics, Intercept, Merz, Norgine, Novartis, Orphalan, Sequana Medical; honoraria or consultation fees\/advisory board: from Abbvie, Alexion, Albireo, Bayer, Gilead, GSK, Eisai, Enyo Pharma, HepaRegeniX GmbH, Humedics, Intercept, Ipsen, Janssen, MSD\/Merck, Novartis, Orphalan, Roche, Sequana Medical, SIRTEX, SOBI, and Shionogi and participated in a company sponsored speaker\u2019s bureau: Abbvie, Advance Pharma, Alexion, Albireo, Bayer, Gilead, Eisai, Falk Foundation, Intercept, Ipsen, Janssen, MedUpdate GmbH, MSD\/Merck, Novartis, Orphalan, Sequana Medica, SIRTEX, and SOBI.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"N\/A.","order":4,"name":"Ethics","label":"Registry and Registration No. of the study\/trail","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"N\/A.","order":5,"name":"Ethics","label":"Animal studies","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"N\/A.","order":6,"name":"Ethics","label":"Research involving recombinant DNA","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"184"}}